Trademark: 87252603
Word
IO2
Status
Dead
Status Code
606
Status Date
Monday, February 20, 2023
Serial Number
87252603
Mark Type
4000
Filing Date
Wednesday, November 30, 2016
Published for Opposition
Tuesday, November 19, 2019
Abandoned Date
Monday, February 20, 2023

Trademark Owner History
BTG International Limited - Owner At Publication

Classifications
41 (Based on Intent to Use) Provision of education, namely, training in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of education and training, namely, developing, arranging and conducting live and online educational conferences, seminars, classes, lectures, panel discussions, workshops and programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials in connection therewith; Provision of education and training, namely, providing non-downloadable webinars in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials in connection therewith; Provision of education and training, namely, conducting online and telephonic instruction and courses in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of education and training, namely, development of multi-media educational content for use with mobile devices and computers in relation to healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Arranging, and conducting educational conferences and programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision and publication of educational material and content, namely, publication of teaching guides, instructional materials, brochures and providing on-line non-downloadable publications in the nature of teaching guides, instructional materials, and brochures in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Conducting educational seminars in the fields healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials therewith; Information and advice relating to education and training provided online from a computer database or the internet, all relating to healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of educational information, namely, providing on-line instruction in the fields healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care provided on-line from a computer database
5 (Based on 44(e) Pharmaceutical, medicinal and veterinary preparations and substances, namely, vaccines, antitoxic sera, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations and substances for the treatment of thrombosis, embolisms, inflammation, and autoimmune disease, pharmaceutical preparations for the treatment of envenomation by snakes, veterinary preparations for the treatment of envenomation by snakes, liquid medical sealants, and liquid adhesives for use in surgical and clinical procedure; sanitary preparations for medical purposes; vaccines; pharmaceutical and medicinal preparations and substances, namely, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances, and sepsis; medical diagnostic reagents and substances, all for in vivo use; antibodies and therapeutic antibodies for use as anti-lymphocytic agents for medical use; pharmaceutical preparations in the form of foams or for use in producing foams, for sclerotherapy, phlebology, angiology or proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for medical therapeutic and diagnostic purposes; chemical reagents for medical and veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for use in the treatment of pre-eclampsia; chemical preparations for medical or pharmaceutical purposes for use in the prevention and treatment of cancer, circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, and intracranial hemorrhages, cerebral hemorrages, and hematoma; pharmaceutical preparations for the treatment of cancer; pharmaceutical and veterinary preparations for the reduction or elimination of circulating cytokines; pharmaceutical and veterinary preparations for the treatment of hypertension; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of multiple neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for the treatment of immune disorders, namely, type 1 diabetes, psoriasis, coeliac disease and rheumatoid arthritis; pharmaceutical preparations for the treatment of sepsis; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for treatment of envenomation by snakes; pharmaceutical preparations for the treatment of methotrexate toxicity; pharmaceutical preparations for the treatment of cancer including prostate, oesophageal and brain cancer and leukaemias; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical or veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; chemical reagents for medical or veterinary therapeutic and medical diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; chemical preparations for medical or pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; transarterial chemoembolization pharmaceutical preparations, vaccines and antitoxic sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; Pharmaceutical preparations being beads, including microscopic radioactive beads, for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive material for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive pharmaceutical preparations and consisting of radioactive material for treatment of cancerous tumors; radioactive glass beads impregnated with pharmaceutical preparations for the treatment of cancer; irradiated and radioactive microspheres used for in vivo therapeutic medical purposes, namely, beads in the nature of microscopic glass beads impregnated with radioactive pharmaceutical preparations for treatment of cancerous tumors; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and/or medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams or for use in producing foams for sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy and autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents
44 (Based on Intent to Use) Provision of medical and surgical information; Provision of medical and surgical information on-line from a computer database or from the Internet or by telecommunication means; Providing medical information; Providing a website featuring information regarding medicine, medical treatment, medical patient care, therapeutic properties of prescription drugs, pharmaceutical advice, dispensing of pharmaceuticals, medical treatment and medical patient care aftercare; Providing a website featuring medical information regarding medicine, medical treatment, medical patient care, therapeutic properties of prescription drugs, pharmaceutical advice, dispensing of pharmaceuticals, medical treatment and medical patient care aftercare; Providing healthcare information; Providing information about medical devices for use in medical procedures and surgery; Providing information about healthcare; Providing information in the field of healthcare, therapeutic properties of pharmaceuticals, medical devices for use in medical procedures and surgery, surgery, and medicine and medical patient care; Providing information in the field of healthcare, therapeutic properties of pharmaceuticals, medical devices for use in medical procedures and surgery, surgery, and medicine and medical patient care by means of computer, electronic and online databases
10 (Based on 44(e) Surgical, medical, dental and veterinary apparatus and instruments, namely, cryoablation needles, medical syringes, electrically powered tissue ablation devices, artificial limbs, orthopaedic articles, namely, implants made of artificial materials, haemofiltration devices for medical use, apparatus for generating and transmitting ultrasound for medical and diagnostic use, surgical and medical apparatus and instruments for use in minimally invasive cryoablation procedures, electronic apparatus and instruments for use in relation to ultrasound imaging and scanning for medical and diagnostic use, and medical and diagnostic imaging units; Surgical and medical apparatus, instruments and devices for the treatment of chronic lung disease including emphysema; medical syringes, medical cannula needles, medical tubing; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical and medical apparatus and instruments for producing and administering sclerosing foams; surgical and medical apparatus and instruments for producing foams for use in sclerotherapy, phlebology, angiology or proctology, sterilisation treatment or for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; surgical and medical devices for assessing the physical characteristics of such foams, namely, devices for intravenous administration of foam, medical diagnostic apparatus for analyzing the efficacy of sclerotherapy foams for medical purposes, medical diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose, and devices for monitoring the position and effect of foam in the human body; medical diagnostic devices for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins, hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; drug delivery embolisation apparatus, instruments and systems; apparatus and instruments for use in the circulatory system; apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolisation; drug delivery embolisation systems; drug delivery apparatus and instruments comprised of injection syringes, and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation, namely, medical devices in the nature of particles, namely, embolic microspheres for embolization; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; beads, namely, microscopic glass beads, impregnated with radioactive material or containing radioactive material and administered surgically for treatment of cancerous tumours; radioactive beads, namely, radioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system; medical devices which use ultrasound to enhance drug delivery and/or medically activate drugs; catheters for delivery of drugs or fluids sold together as a unit with controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus sold together as a unit with controllers and power units therefor; needles for medical use, namely, cannula needles; medical tubing for sclerotherapy; medical tubing for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; syringes for producing and administering foams for use in sclerotherapy, phlebology, angiology or proctology; surgical and medical apparatus for administering and producing foams for use in sterilisation treatment; surgical and medical apparatus for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hycroceles; syringes for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical devices for monitoring the position and effect of foam in the human body; medical diagnostic apparatus for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins, hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; compression bandages; surgical instruments and apparatus and medical diagnostic apparatus for use in interventional pulmonology; medical devices for use in pulmonary and thoracic surgery and procedures; medical devices for use in pulmonary and thoracic surgery, namely, lung volume reduction devices; artificial surgical implants for use in interventional pulmonology; surgical implants comprising artificial surgical implants for restoring, maintaining and improving patient breathing, and artificial surgical implants for restoring, maintaining and improving lung function; medical devices for performing cryotherapy, namely, cryosurgical probes and cryoablation needles used for the minimally invasive cryoablation of cancerous and benign tissues; medical apparatus consisting of treatment probes and high pressure valves used for heat or freeze treatment incorporating computer software; surgical instruments and apparatus and medical diagnostic apparatus for use in cryoablation, and the treatment of prostate cancer, kidney or renal tumours, and benign prostatic hyperplasia (BPH ); medical devices used to deliver heat to target sites using electrical current through needles; medical devices to deliver cryogen gas for freezing and either cryogen gas or electrical current for heating for treatment of cancer and tumors ; medical devices for ablating human and animal tissue using microwave energy; medical devices for treating cancerous and benign tissue using microwave energy; replacement and structural parts and fittings for all of the aforesaid goods
42 (Based on Intent to Use) Providing on-line, non-downloadable educational software featuring instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; Information about medical research; Providing educational information in the field of medical research; Providing educational information in the field of medical research by means of computer, electronic and online databases; Information about pharmaceutical research; Providing educational information in the field of pharmaceutical research; Providing educational information in the field of pharmaceutical research by means of computer, electronic and online databases

Trademark Events
Feb 21, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Feb 20, 2023
Abandonment - No Use Statement Filed
May 21, 2022
Notice Of Approval Of Extension Request E-Mailed
May 20, 2022
Sou Extension 5 Granted
May 18, 2022
Sou Extension 5 Filed
May 18, 2022
Sou Teas Extension Received
Mar 3, 2022
Notice Of Approval Of Extension Request E-Mailed
Mar 2, 2022
Sou Extension 4 Granted
Dec 6, 2021
Sou Extension 4 Filed
Feb 28, 2022
Case Assigned To Intent To Use Paralegal
Dec 6, 2021
Sou Teas Extension Received
May 26, 2021
Notice Of Approval Of Extension Request E-Mailed
May 25, 2021
Sou Extension 3 Granted
May 17, 2021
Sou Extension 3 Filed
May 24, 2021
Case Assigned To Intent To Use Paralegal
May 17, 2021
Sou Teas Extension Received
Apr 21, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Apr 21, 2021
Teas Change Of Correspondence Received
Apr 21, 2021
Teas Change Of Owner Address Received
Jan 13, 2021
Notice Of Approval Of Extension Request E-Mailed
Jan 11, 2021
Sou Extension 2 Granted
Jan 11, 2021
Sou Extension 2 Filed
Jan 11, 2021
Sou Teas Extension Received
Aug 30, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 30, 2020
Teas Change Of Correspondence Received
Aug 30, 2020
Teas Withdrawal Of Attorney Received-Firm Retains
Aug 30, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 30, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 30, 2020
Teas Change Of Owner Address Received
Jul 8, 2020
Notice Of Approval Of Extension Request E-Mailed
Jul 6, 2020
Sou Extension 1 Granted
Jul 6, 2020
Sou Extension 1 Filed
Jul 6, 2020
Sou Teas Extension Received
Jan 14, 2020
Noa E-Mailed - Sou Required From Applicant
Nov 19, 2019
Official Gazette Publication Confirmation E-Mailed
Nov 19, 2019
Published For Opposition
Oct 30, 2019
Notification Of Notice Of Publication E-Mailed
Oct 17, 2019
Exparte Appeal Terminated
Oct 17, 2019
Approved For Pub - Principal Register
Sep 27, 2019
Examiner's Amendment Entered
Sep 27, 2019
Notification Of Examiners Amendment E-Mailed
Sep 27, 2019
Examiners Amendment E-Mailed
Sep 27, 2019
Examiners Amendment -Written
Aug 29, 2019
Teas/Email Correspondence Entered
Aug 29, 2019
Correspondence Received In Law Office
Aug 23, 2019
Teas Request For Reconsideration Received
Aug 23, 2019
Ex Parte Appeal-Instituted
Aug 23, 2019
Jurisdiction Restored To Examining Attorney
Aug 23, 2019
Exparte Appeal Received At Ttab
Feb 25, 2019
Notification Of Final Refusal Emailed
Feb 25, 2019
Final Refusal E-Mailed
Feb 25, 2019
Final Refusal Written
Feb 8, 2019
Data Modification Completed
Feb 7, 2019
Teas/Email Correspondence Entered
Feb 7, 2019
Correspondence Received In Law Office
Feb 1, 2019
Teas Response To Suspension Inquiry Received
Oct 2, 2018
Report Completed Suspension Check Case Still Suspended
Sep 11, 2018
Suspension Checked - To Attorney For Action
Mar 6, 2018
Report Completed Suspension Check Case Still Suspended
Mar 2, 2018
Suspension Checked - To Attorney For Action
Sep 2, 2017
Notification Of Letter Of Suspension E-Mailed
Sep 2, 2017
Letter Of Suspension E-Mailed
Sep 2, 2017
Suspension Letter Written
Aug 23, 2017
Teas/Email Correspondence Entered
Aug 22, 2017
Correspondence Received In Law Office
Aug 22, 2017
Teas Response To Office Action Received
Mar 7, 2017
Notification Of Non-Final Action E-Mailed
Mar 7, 2017
Non-Final Action E-Mailed
Mar 7, 2017
Non-Final Action Written
Mar 4, 2017
Assigned To Examiner
Feb 1, 2017
Preliminary/Voluntary Amendment - Entered
Jan 31, 2017
Assigned To Lie
Jan 12, 2017
Teas Voluntary Amendment Received
Dec 6, 2016
New Application Office Supplied Data Entered
Dec 3, 2016
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24